170808 ⎘
Detection or diagnosis of diseases; Hepato-biliairy disorders other than hepatitis Liver diseases, e.g. portal hypertension, fibrosis, cirrhosis, bilirubin
MARKERS FOR THE DIAGNOSIS AND TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCED LIVER FIBROSIS
#2SOLID DOSAGE FORM FOR THE TREATMENT OF PRIMARY BILIARY CHOLANGITIS
#3A COMPOUND AND ITS USE FOR DETECTING A DISEASE IN THE EXHALED BREATH OF A SUBJECT
#4MEASURING RISK OF ADVERSE CLINICAL EVENTS IN CHRONIC LIVER DISEASE
#5BIOMARKERS OF FIBROSIS AND USES THEREFOR
#6MASS SPECTROMETRIC ANALYSIS OF BIOMARKERS
#7ASSESSMENT OF CHRONIC LIVER DISEASE
#8APPLICATION OF BIOMARKER IN PREPARING METABOLIC DYSFUNCTION-ASSOCIATED STEATOTIC LIVER DISEASE CLASSIFICATION PRODUCTS
#9METHODS FOR TREATING CHOLESTASIS
#10SERINE PROTEASE INHIBITOR KAZAL (SPIK) COMPOSITIONS AND METHODS
#11BIOLOGICAL MARKERS OF LIVER FAT
#12Detection of Liver Disease
#13PERSONALIZED LIVER CANCER TREATMENT
#14METHODS FOR MONITORING TREATMENT OF CHRONIC LIVER DISEASE
#15METHODS FOR PREDICTION AND EARLY DETECTION OF DIABETES
#16IMPROVED DIAGNOSIS OF NONALCOHOLIC STEATOHEPATITIS
#17METHODS OF TREATING AND DIAGNOSING FATTY LIVER DISEASE
#18MARKERS FOR PROGRESSION OF INFLAMMATORY LIVER DISEASE
#19LIVER DISEASE TREATMENT AND ASSESSMENT USING OXYLIPINS
#20METHOD FOR IDENTIFYING LIVER FIBROSIS
#21METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS BIOMARKER COMPOSITIONS AND APPLICATIONS THEREOF
#22Point of Care Assays
#23METHODS, SYSTEMS AND COMPOSITIONS FOR THE PREDICTION AND PREVENTION OF PARENTERAL NUTRITION ASSOCIATED CHOLESTASIS USING FECAL BIOMARKERS
#24ASSESSMENT AND DETECTION OF PORTAL VEIN THROMBOSIS IN CHRONIC LIVER DISEASE AND STAGING THEREOF
#25EX VIVO PROTEASE ACTIVATION AND DETECTION
#26INFORMATIVE BIOMARKERS OF PORTAL HYPERTENSION
#27DISEASE DETECTION WITH COMBINATORIAL BIOMARKERS
#28METHODS AND COMPOSITIONS FOR TREATING LIVER DISEASE
#29Application of Lipid Biomarkers in Diagnosis and Early Warning of Fatty Liver in Periparturient Dairy Cows
#30Biomarker for Detecting Hepatocytes With Bile Ductular Proliferation
#31Application of Organic Acids in Urine for Health Management
#32COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING METABOLIC DISEASES AND/OR A CLINICAL CONDITION THEREOF
#33BIOMARKERS FOR TREATING LIVER DISORDERS WITH THR-B AGONISTS AND RELATED USES
#34USE OF SOLUBLE TREM2 AS A NON-INVASIVE BIOMARKER FOR NON-ALCOHOLIC STEATOHEPATITIS (NASH)
#35NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC STEATOHEPATITIS
#36NON-INVASIVE MONITORING OF LIVER DISEASE TREATMENT
#37METHODS FOR ASSESSING TREATMENT WITH A GASTROINTESTINAL IMPLANT
#38BIOMARKERS TO DETECT RISK OF SINUSOIDAL OBSTRUCTION SYNDROME
#39METHOD FOR ASSESSMENT OF HEPATIC FUNCTION AND PORTAL BLOOD FLOW
#40APPLICATION OF NEONATAL BILIARY ATRESIA BIOMARKER AND DETECTION METHOD FOR SAME
#41ANTIBODIES AND METHODS FOR THE DETECTION OF CELL DEATH
#42COMPOUNDS, COMPOSITIONS, AND METHODS FOR TREATING OR AMELIORATING NONALCOHOLIC FATTY LIVER DISEASE AND RELATED DISEASES OR DISORDERS
#43METHODS AND COMPOSITIONS FOR DETERMINATION NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NON-ALCOHOLIC STEATOHEPATITIS (NASH)
#44FIBROSIS BIOMARKERS FOR NON-ALCOHOLIC FATTY LIVER DISEASE
#45Protein Biomarkers For Non-Alcoholic Fatty Liver Disease (NAFLD)
#46METHODS FOR TREATING CHOLESTASIS
#47METHODS FOR TREATING CHOLESTASIS
#48DIAGNOSTIC AGENT AND MEDICINE COMPRISING ADAMTS13 AS MAIN INGREDIENT
#49METHOD FOR DIAGNOSING PRIMARY BILIARY CIRRHOSIS (PBC) USING NOVEL AUTOANTIGENS
#50METHODS OF DETECTING ADVANCED LIVER FIBROSIS OR HEPATOCELLULAR CARCINOMA BIOMARKERS IN A SAMPLE
#51DIAGNOSTIC METHODS FOR LIVER DISORDERS
#52Non-Invasive Method and System for Classifying a Liver Condition in a Human Subject
#53ALPHA-1 ANTITRYPSIN (AAT) RNAI AGENTS, COMPOSITIONS INCLUDING AAT RNAI AGENTS, AND METHODS OF USE
#54MARKER FOR DIAGNOSIS OF NONALCOHOLIC FATTY LIVER DISEASE
#55LIPOPEPTIDES FOR USE IN TREATING LIVER DISEASES AND CARDIOVASCULAR DISEASES
#56Biomarkers for diagnosing non-alcoholic steatohepatitis (NASH) or hepatocellular carcinoma (HCC)
#57BIOMARKER COMBINATIONS TO SIMULTANEOUSLY EVALUATE NON-ALCOHOLIC STEATOHEPATITIS AND HEPATIC FIBROSIS STATUS
#58Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof
#59METHOD OF DIAGNOSING AND TREATING NONALCOHOLIC FATTY LIVER DISEASE AND NONALCOHOLIC STEATOHEPATITIS
#60IHH AS A BIOMARKER AND THERAPEUTIC TARGET FOR NONALCOHOLIC STEATOHEPATITIS (NASH)
#61Methods Of Detecting And Treating Hepatocellular Carcinoma
#62METHODS OF MONITORING ALPHA-1 ANTITRYPSIN (AAT) DEFICIENCY BY MEASURING POLYMERISED AAT
#63Assay method for the detection of VCAM-1 and alpha-2-macroglobulin in blood
#64Biomarker of Fibrosis
#65METHODS OF DIAGNOSTIC OF LIVER FIBROSIS
#66MODIFIED FIBROBLAST GROWTH FACTOR 21 (FGF-21) FOR USE IN METHODS FOR TREATING NONALCOHOLIC STEATOHEPATITIS (NASH)
#67Application of microbiological markers in non-invasive identification/early warning of fatty liver in perinatal cows
#68Methods for Using Collagen Hybridizing Peptides to Determine Collagen Content
#69DIAGNOSTIC METHODS FOR LIVER DISORDERS
#70COMPOSITIONS AND METHODS FOR DIAGNOSING PRIMARY BILIARY CIRRHOSIS
#71METHOD FOR DIAGNOSING NONALCOHOLIC STEATOHEPATITIS
#72COMPOSITION FOR PREVENTING OR TREATING LIVER FIBROSIS, CONTAINING TRIAZOLE DERIVATIVE AS ACTIVE INGREDIENT
#73Biomarkers in Primary Biliary Cholangitis
#74MICROFLUIDIC BASED ASSAY FOR UNBOUND BILIRUBIN
#75TRANSMEMBRANE pH-GRADIENT POLYMERSOMES
#76CXCL14 AS PREDICTIVE BIOMARKER FOR ACUTE LIVER FAILURE AND DEATH
#77METHOD FOR NASH RISK ASSESSMENT
#78NON INVASIVE METHODS FOR DIAGNOSING LIVER FIBROSIS
#79DEVELOPMENT OF BLOOD FIBROSIS MARKER FOR NON-ALCOHOLIC STEATOHEPATITIS
#80Method of making a polymersome
#81SITE- AND STRUCTURE-SPECIFIC CORE FUCOSYLATION IN LIVER DISEASE
#82MARKERS FOR THE DIAGNOSIS AND TREATMENT OF NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND ADVANCE LIVER FIBROSIS
#83Methods for treating cholestasis
#84Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment
#85DIAGNOSTIC AGENT AND MEDICINE COMPRISING ADAMTS13 AS MAIN INGREDIENT
#86ASSAY METHOD FOR THE DETECTION OF VCAM-1 AND ALPHA-2-MACROGLOBULIN IN BLOOD
#87Clinical diagnosis of non-alcoholic fatty liver disease using a panel of human blood protein biomarkers
#88USE OF A GROUP OF MARKERS FOR DIAGNOSING AND ADJUSTING TREATMENT OF PRIMARY BILIARY CHOLANGITIS, PHARMACEUTICAL COMPOSITION AND SOLID DOSAGE FORM FOR TREATING PRIMARY BILIARY CHOLANGITIS
#89ASSESSING AND TREATING ALCOHOL-ASSOCIATED LIVER DISEASE
#90BIOMARKERS
#91METHODS FOR THE ASSESSMENT OF RISK AND TREATMENTS FOR LIVER CANCERS AND LETHAL LIVER DISEASE COMPLICATIONS
#92Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof
#93DIAGNOSIS AND TREATMENT OF NAFLD AND LIVER FIBROSIS
#94NOVEL PATHOLOGICAL MARKER AND USES THEREOF
#95DETECTING GUT BARRIER DYSFUNCTION AND/OR CIRRHOSIS
#96METHODS FOR DIAGNOSING AND EVALUATING NON-ALCOHOLIC STEATOHEPATITIS
#97METHODS AND COMPOSITIONS FOR DETERMINATION OF LIVER FIBROSIS
#98ANTI-SERINE PROTEASE INHIBITOR KAZAL (SPIK) ANTIBODIES, IMMUNOCONJUGATES, AND METHODS OF USE
#99HSD17B13 variants and uses thereof
#100FIBROSIS-SPECIFIC CELL CULTURE SUBSTRATE AND METHODS OF USE
#101OPTIMIZED FRAGMENTATION FOR QUANTITATIVE ANALYSIS OF FUCOSYLATED N-GLYCOPROTEINS BY LC-MS-MRM
#102BIOTHIOL-ACTIVATABLE PROBE AND METHOD OF USE
#103Method To Evaluate Metabolic Activity Of Liver Enzymes
#104Combination of biomarkers for detecting and evaluating a hepatic fibrosis
#105TREATMENT OF AUTOIMMUNE LIVER DISEASE
#106METHOD FOR THE DIAGNOSTIC AND/OR PROGNOSTIC ASSESSMENT OF ACUTE-ON-CHRONIC LIVER FAILURE SYNDROME IN PATIENTS WITH LIVER DISORDERS
#107Biomarkers for diagnosing non-alcoholic steatohepatitis (NASH) or hepatocellular carcinoma (HCC)
#108Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment
#109TEST TO ASSESS LIVER DISEASE SEVERITY
#110Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
#111DIAGNOSIS OF NON-ALCOHOLIC STEATOHEPATITIS
#112METHODS FOR TREATING CHOLESTASIS
#113PREVENTION OR TREATMENT OF FIBROTIC DISEASE
#114ANTIBODIES TO OXIDATION-SPECIFIC EPITOPES
#115EX VIVO PROTEASE ACTIVITY DETECTION FOR DISEASE DETECTION/DIAGNOSTIC, STAGING, MONITORING AND TREATMENT
#116Ex vivo protease activity detection for disease detection/diagnostic, staging, monitoring and treatment
#117IMMUNOASSAY METHOD FOR FREE AIM IN BIOLOGICAL SAMPLE, AND METHOD FOR DETECTING NASH IN SUBJECT
#118Methods for treating cholestasis
#119DIAGNOSIS AND MONITORING OF LIVER DISEASE
#120Antibodies and Methods for the Detection of Cell Death
#121APPLICATION OF ECM1 IN PREVENTION AND/OR TREATMENT OF LIVER FIBROSIS-RELATED DISEASES
#122METHOD FOR DIAGNOSING A LIVER DISEASE
#123METHODS FOR MONITORING TREATMENT OF CHRONIC LIVER DISEASE
#124Method for Detecting Liver Diseases
#125Methods for diagnosing and/or treating acute or chronic liver, kidney or lung disease
#126METHODS AND KITS FOR DETECTING LIVER DYSFUNCTION IN A SUBJECT
#127METHODS TO PREDICT LIVER DISEASE MORTALITY USING LIPOPROTEIN LP-Z
#128Nanoveson(TM): Treatment, Biomarkers and Diagnostic Tests for Liver Diseases and Comorbid Diseases
#129COMPOSITIONS AND METHODS FOR SUPPRESSING AND/OR TREATING METABOLIC DISEASES AND/OR A CLINICAL CONDITION THEREOF
#130METHOD FOR FUNCTIONAL CHARACTERISTICS OF PROTEINS FOR CLASSIFICATION OF PATIENTS TO BE ASSOCIATED TO A SPECIFIC DISEASE
#131USES OF 4210 DA PEPTIDE AS A MARKER IN DIAGNOSIS OF LIVER CANCER AND CIRRHOSIS
#132METHOD FOR PROVIDING INFORMATION ON DIAGNOSIS OR PROGNOSTIC MEASUREMENT OF HISTOLOGICAL SEVERITY OF NONALCOHOLIC FATTY LIVER DISEASE
#133Clinical Gene Signature-Based Human Cell Culture Model and Uses Thereof
#134SYSTEMS AND METHODS FOR SPECTRAL IMAGING CHARACTERIZATION OF MACROPHAGES FOR USE IN PERSONALIZATION OF TARGETED THERAPIES TO PREVENT FIBROSIS DEVELOPMENT IN PATIENTS WITH CHRONIC LIVER DISEASE
#135DIAGNOSTIC METHODS FOR LIVER DISORDERS
#136Serine protease inhibitor kazal (SPIK) compositions and methods
#137SYNERGISTIC COMBINATION OF BIOMARKERS FOR DETECTING AND ASSESSING HEPATIC FIBROSIS
#138Method and System for Identifying and Classifying a Liver Condition in a Human Subject
#139METHOD OF DIAGNOSIS OF LIVER STEATOSIS
#140Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) Biomarkers and Uses Thereof
#141METHOD FOR AIDING DETECTION OF NONALCOHOLIC STEATOHEPATITIS
#142METHOD FOR DIAGNOSING LIVER DISEASES AND METHOD FOR SCREENING THERAPEUTIC AGENT FOR LIVER DISEASES USING CHANGES IN EXPRESSION OF TM4SF5 PROTEIN
#143Kit for tracking and diagnosing degree of progressive chronic hepatitis and liver fibrosis by measuring asialo (alpha)1-acid glycoprotein as hepatocellular injury marker and use thereof
#144USE OF CIRCULATING CELL BIOMARKERS IN THE BLOOD FOR DETECTION AND DIAGNOSIS OF DISEASES AND METHODS OF ISOLATING THEM
#145METHODS FOR TREATING CHOLESTASIS
#146Modified fibroblast growth factor 21 (FGF-21) for use in methods for treating nonalcoholic steatohepatitis (NASH)
#147BREATH TEST DEVICE AND METHOD
#148BIOMARKER AND TREATMENT TARGET FOR ALCOHOLIC HEPATITIS
#149Treatment of necroptosis
#150Treatment of pyroptosis
#151Diagnosis of Liver Pathology Through Assessment of Protein Glycosylation
#152METHODS FOR DIAGNOSIS AND INTERVENTION OF HEPATIC DISORDERS
#153METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS
#154Liver Disease
#155Lipopeptides for Use in Treating Liver Diseases and Cardiovascular Diseases
#156Liver Disease
#157Liver disease-related biomarkers and methods of use thereof
#158HUMAN MICROPHYSIOLOGICAL CELL SYSTEM FOR LIVER DISEASE CONVERSTION PROV 1-18585 AND PROV 2-19154
#159Eplerenone for phenotyping of CYP3A5 enzyme activity in saliva samples
#160Methods for prediction and early detection of diabetes
#161PD Marker of Hepatocyte Growth Factor (HGF)
#162Use of leucine-zipper protein for diagnosis or treatment of fatty liver
#163COMPOSITIONS AND METHODS FOR IDENTIFYING AND TREATING LIVER DISEASES AND MONITORING TREATMENT OUTCOMES
#164Method for assessment of hepatic function and portal blood flow
#165Treating Renal and Liver Dysfunction with TLR4 Antagonists
#166GUT BACTERIA IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE AND METHODS THEREWITH IN DETECTING ILEAL FIBROSIS
#167METHODS OF DIAGNOSIS AND TREATMENT OF LIVER DISEASES USING OBETICHOLIC ACID
#168BIOMARKER OF PNPLA3 EXPRESSION
#169PRE-TRANSPLANT TCR CLONALITY ASSESSMENT TO PREDICT POST-LIVER TRANSPLANT SURVIVAL
#170COMPOSITION FOR PREDICTING OR DIAGNOSING LIVER DISEASE, AND LIVER DISEASE PREDICTION OR DIAGNOSIS METHOD USING SAME
#171Biomarkers related to organ function
#172Diagnostic agent and medicine comprising ADAMTS13 as main ingredient
#173Transmembrane pH-gradient polymersomes for the quantification of ammonia in body fluids
#174Serum/plasma LncRNA marker composition associated with auxiliary diagnosis of intrahepatic cholestasis of pregnancy and application thereof
#175Liver Fibrosis Assessment Model, Liver Fibrosis Assessment System And Liver Fibrosis Assessment Method
#176Biomarker combinations to simultaneously evaluate non-alcoholic steatohepatitis and hepatic fibrosis status
#177NON-INVASIVE DIAGNOSTIC OF NON-ALCOHOLIC FATTY LIVER DISEASES, NON-ALCOHOLIC STEATOHEPATITIS AND/OR LIVER FIBROSIS
#178COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF DISEASES OF THE LIVER
#179METHODS AND KITS FOR PREDICTING THE TRANSPLANTATION-FREE SURVIVAL TIME OF PATIENTS SUFFERING FROM CIRRHOSIS
#180Target marker GP73 for detecting steatohepatitis and detection application method
#181Biomarkers in autoimmune liver disease
#182Non-invasive diagnostic of non-alcoholic fatty liver diseases, non-alcoholic steatohepatitis and/or liver fibrosis
#183Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
#184Methods for detecting sinusoidal obstructive syndrome (SOS)
#185Phenotypic profiling of hepatocellular carcinoma circulating tumor cells for treatment selection
#186Liver disease
#187METHOD FOR DETECTING THE QUANTITY OF BIOMARKER AND IDENTIFYING DISEASE STATUS
#188BIOMARKERS FOR LIVER FUNCTION
#189Method of Assessing Liver Triglyceride Levels Using a Body Fluid Sample
#190Use of engineered liver tissue constructs for modeling liver disorders
#191Methods for assessing treatment with a gastrointestinal implant
#192DIAGNOSTIC METHODS FOR LIVER DISORDERS
#193COMBINATION OF BIOMARKERS FOR DETECTING AND EVALUATING A HEPATIC FIBROSIS
#194SUBSTRATES RECOGNIZED BY FIBROBLAST ACTIVATION PROTEIN (FAP) AND METHODS OF USING THE SAME
#195Antibodies and methods for the detection of cell death
#196DIAGNOSTIC METHODS FOR LIVER DISORDERS
#197LIVER DISEASE
#198Diagnostic method of liver cancer using α-fetoprotein derived glycopeptides by mass spectrometry
#199Method of diagnosis of drug induced liver injury
#200NON-INVASIVE DIAGNOSIS OF FIBROTIC NON-ALCOHOLIC STEATOHEPATITIS
#201Differential diagnosis of liver disease
#202Methods and devices for assessing in vivo toxic levels of bilirubin and diagnosing increased risk of bilirubin neurotoxicity
#203Diagnosis and monitoring of liver disease
#204Activity sensor with tunable analyte
#205Method of detecting biological material, and chemiluminescent indicator used therein
#206Non-invasive diagnostic of non-alcoholic steatohepatitis
#207Methods for monitoring treatment of chronic liver disease
#208Clinical diagnosis of non-alcoholic fatty liver disease using a panel of human blood protein biomarkers
#209SYSTEM AND METHODS FOR BILIRUBIN ANALYSIS
#210Anti-GP73 monoclonal antibodies and methods of obtaining the same
#211Non-alcoholic fatty liver regulator 14-3-3 protein
#212Use of leucine-zipper protein for diagnosis or treatment of fatty liver
#213NOVEL LIVER CIRRHOSIS OR LIVER FIBROSIS MARKER
#214Diagnostics and methods for treatment of non-alcoholic hepatic steatosis and hepatic steatohepatitis, and prevention of complications thereof
#215Serologic assay of liver fibrosis
#216System and methods for bilirubin analysis
#217Antibodies to oxidation-specific epitopes
#218Diagnostic methods based on lipid profiles
#219Method for assessment of hepatic function and portal blood flow
#220METHOD FOR MEASURING A BIOLOGICAL VALUE OF A LIVER
#221NOVEL CELL CULTURE METHOD, CELL CULTURE SYSTEM AND USES THEREOF
#222Use of lyso-Gb1 as druggable target
#223METHOD FOR OBTAINING USEFUL DATA FOR THE DIFFERENTIAL DIAGNOSIS OF LIVER FIBROSIS
#224Macrophage stimulating protein receptor (or RON—recepteur d'Origine Nantais) antibodies and uses thereof
#225Lipopeptides for use in treating liver diseases and cardiovascular diseases
#226NON-INVASIVE METHOD FOR ASSESSING THE PRESENCE AND SEVERITY OF ESOPHAGEAL VARICES
#227Methods for diagnosis and intervention of hepatic disorders
#228Free radical consumption speed information acquisition method and NASH determination method
#229Glucagon/GLP-1 receptor co-agonists
#230Methods of therapeutic monitoring of nitrogen scavenging drugs
#231Biomarkers for Fatty Liver Disease and Methods Using the Same
#232System and methods for bilirubin analysis
#233Process for in vitro diagnosis of hepatic disorders
#234Method for predicting risk of exposure to interstitial fibrosis and tubular atrophy with clusterin
#235METABOLOMIC SIGNATURE OF DIAGNOSIS AND DISEASE PROGRESSION IN NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD)
#236Biomarkers for Diagnosing Liver Disease
#237Methods for diagnosing and evaluating non-alcoholic steatohepatitis
#238Methods of therapeutic monitoring of nitrogen scavenging drugs
#239Methods of therapeutic monitoring of nitrogen scavenging drugs
#240Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) biomarkers and uses thereof
#241Methods for molecular classification of fatty liver by high-throughput protein post-translational modifications
#242Treating hyperammonemia, reducing plasma ammonia with TLR4 antagonists
#243Use of circulating cell biomarkers in the blood for detection and diagnosis of diseases and methods of isolating them
#244Methods of therapeutic monitoring of nitrogen scavenging drugs
#245Methods of therapeutic monitoring of nitrogen scavenging drugs
#246Methods of therapeutic monitoring of nitrogen scavenging drugs
#247Methods of therapeutic monitoring of nitrogen scavenging drugs
#248Methods of therapeutic monitoring of nitrogen scavenging drugs
#249Treatment and prevention of muscle loss using L-ornithine in combination with at least one of phenylacetate and phenylbutyrate
#250HSD17B13 variants and uses thereof
#251Non-alcoholic fatty liver regulator 14-3-3 protein
#252Methods and compositions for treatment of autoimmune hepatitis
#253Devices and formulations for detecting, screening and monitoring levels of certain constituents in bodily fluids and method
#254NON-ALCOHOLIC FATTY LIVER REGULATING FACTOR 14-3-3 PROTEIN
#255Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use
#256DIAGNOSTIC METHODS FOR LIVER DISORDERS
#257Nanoveson(TM): Treatment, Biomarkers and Diagnostic Tests for Liver Diseases and Comorbid Disease
#258NON-ALCOHOLIC FATTY LIVER DISEASE BIOMARKERS
#259Method for screening pharmaceuticals for treatment of steatohepatitis using N-terminal dimerization of apoptosis signal-regulated kinase1
#260Clinical gene signature-based human cell culture model and uses thereof
#261METHOD FOR DETECTING THE QUANTITY OF BIOMARKER AND IDENTIFYING DISEASE STATUS
#262METHOD FOR MEASURING GLYCOPROTEIN, METHOD FOR EXAMINING LIVER DISEASE, REAGENT FOR QUANTITATIVE DETERMINATION OF GLYCOPROTEIN, AND GLYCAN-MARKER GLYCOPROTEIN AS AN INDEX FOR CLINICAL CONDITIONS OF LIVER DISEASE
#263Method for Discriminating Symptom of Hepatic Disease
#264Optical probes for matrix metalloproteinases
#265Use of VAP-1 inhibitors for treating fibrotic conditions
#266Vitamin D receptor/SMAD genomic circuit gates fibrotic response
#267Methods of therapeutic monitoring of nitrogen scavenging drugs
#268Methods and compositions for identifying non-alcoholic fatty liver disease
#269BIOMARKERS OF ACUTE LIVER INJURY
#270Disease severity index for assessment of chronic liver disease
#271Articles for diagnosis of liver fibrosis
#272METHODS OF THERAPEUTIC MONITORING OF NITROGEN SCAVENGING DRUGS
#273Methods of therapeutic monitoring of nitrogen scavenging drugs
#274Biomarkers related to kidney function and methods involving their use
#275Methods of therapeutic monitoring of nitrogen scavenging drugs
#276Biomarkers useful in liver fibrosis diagnosis
#277Biomarkers for Fatty Liver Disease and Methods Using the Same
#278ADAM12 inhibitors and their use against inflammation-induced fibrosis
#279Glucagon/GLP-1 receptor co-agonists
#280Method for measuring bile salt export transport and/or formation activity
#281Non-invasive method for assessing liver fibrosis progression
#282THERAPEUTIC AND DIAGNOSTIC METHODS RELATED TO LYSYL OXIDASE-LIKE 2 (LOXL2)
#283Method for diagnosing primary biliary cirrhosis (PBC) using novel autoantigens
#284METHOD FOR DETERMINING DELETIONS IN HBV PRE-S2 REGION
#285Bile acid biomarkers for Niemann-Pick diseases, methods and uses therefor
#286Combination of biomarkers for detecting and evaluating a hepatic fibrosis
#287Nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) biomarkers and uses thereof
#288Energy malnutrition evaluation for liver disease test subject
#289Antibodies and methods for the detection of cell death
#290MEANS AND METHODS TO DIAGNOSE LIVER TOXICITY USING PUTRESCINE AS BIOMARKER
#291Fibrosis biomarker assay
#292Synergistic combination of biomarkers for detecting and assessing hepatic fibrosis
#293Methods of treatment of primary sclerosing cholangitis
#294METABOLICS BIOMARKER FOR NAFLD AND METHODS OF USE
#295Nanoveson(TM): Treatment, Biomarkers and Diagnostic Tests for Liver Diseases and Comormid Disease
#296Human liver scaffolds
#297Anti-GP73 monoclonal antibodies and methods of obtaining the same
#298DIAGNOSIS OF LIVER FIBROSIS OR CIRRHOSIS
#299Diagnostic methods for liver disorders
#300Method for assessment of hepatic function and portal blood flow